Reset
Showing 3 of 3 academic articles

ROS/Enzyme Dual-Responsive Drug Delivery System for Targeted Colorectal Cancer Therapy: Synergistic Chemotherapy, Anti-Inflammatory, and Gut Microbiota Modulation

Xin Zhang, Ruonan Lian, Bingbing Fan, Lei Meng et al. • Pharmaceutics (2025)

Objectives: Colorectal cancer (CRC) is a leading cause of cancer-related mortality, driven by chronic inflammation, gut microbiota dysbiosis, and complex tumor microenvironment interactions. Current therapies are limited by systemic toxicit...

DOAJ Open Access (DOAJ) DOI: 10.3390/pharmaceutics17070940

Lysosome blockade induces divergent metabolic programs in macrophages and tumours for cancer immunotherapy

Jing Ma, Ruijuan Ma, Xueke Zeng, Liming Zhang et al. • Journal of Experimental & Clinical Cancer Research (2023)

Abstract Background Platinum-drugs based chemotherapy in clinic increases the potency of tumor cells to produce M2 macrophages, thus leading to poor anti-metastatic activity and immunosuppression. Lysosome metabolism is critical for cancer ...

DOAJ Open Access (DOAJ) DOI: 10.1186/s13046-023-02768-0